Edwards Lifesciences

Pricing power is strong, evidenced by roughly 78 percent gross margin and stable premium positioning in TAVR and surgical valves. Clinical differentiation and regulatory exclusivity underpin value‑based pricing, while the expanding indications (asymptomatic severe AS) increase addressable patients without commoditizing the therapy.

However, reimbursement pressure, tender dynamics ex‑U.S., and long‑term ASP headwinds from competition are constraints. In TMTT and HF sensors, latent pricing power exists due to procedure‑level economics and hospital outcomes, but adoption curves and CED requirements can defer monetization.